Former Amgen Chief Medical Officer, John Tsai, has joined Novartis as Head of Global Drug Development and Chief Medical Officer.
Tsai has been Chief Medical Officer and Senior Vice President of Global Medical at Amgen since May 2017 and oversees all clinical and medical functions across multiple sites worldwide.
Prior to joining Amgen, Tsai spent eleven years with Bristol-Myers Squibb (BMS), where he served as Global Head of Clinical Development for marketed products and global clinical operations.
At Novartis, he will be responsible for advancing the company’s industry-leading pipeline of innovative medicines and biosimilars.
He will also lead the GDD organisation’s ongoing transformation embracing the power of advanced data sciences and digital technologies to create a more agile model for drug development.